Conference Reports for NATAP

Back

IDSA ID Week 2026 October 21-24 Washington, DC     HIV   Potential Drug-Drug Interactions in People Living With HIV on Antiretroviral Therapy Stratified by Age and Sex - (10/22/26)   Switching to Islatravir + Ulonivirine Once Weekly Maintained HIV-1 Viral Suppression at Week 24 in the Presence of Baseline Nonnucleoside Reverse Transcriptase Inhibitor Resistance-Associated Mutations and M184I/V in Proviral DNA - (10/22/26)   Exposure-Response Analysis of Islatravir 0.25 mg With Doravirine 100 mg Once Daily in Treatment-Naive and Virologically Suppressed People Living With HIV-1 at Week 48 - (10/22/26)   FIVE YEARS OF U.S. REAL-WORLD EVIDENCE REINFORCE THE DURABLE EFFECTIVENESS AND LONG-TERM PERSISTENCE OF ViiVHEALTHCARE'S CABENUVA - (10/22/26)   Gilead to Present New Data Across HIV and Emerging Antiviral Research at IDWeek 2026 - (10/22/26)   PrEP   Exploring Preferences and Adherence & Persistence among Individuals Initiating PrEP in Portugal: the POSITIVE CARE Study - (10/22/26)   Barriers to PrEP, HIV knowledge and perceived stigma among MSM and Heterosexual People Living with HIV in Portugal: the POSITIVE CARE Study - (10/20/26)   Baseline Characteristics and Substance Use Among People Who Inject Drugs With Evidence of Active Use in HPTN 103/PURPOSE 4: A Phase 2 Study of Twice-Yearly Subcutaneous Lenacapavir for Pre-Exposure Prophylaxi - (10/20/26)   Comorbidities/ Aging   Ten-Year Cost Projections for Medicare Beneficiaries 65 Years or Older With HIV - (10/23/26)   Projected Aging Among People With HIV in the US - (10/23/26)   Pharmacokinetic and Clinical Data Supporting the LEN Reloading Strategy for BIC/LEN Single-Tablet Regimen Dosing in the ARTISTRY Studies - (10/22/26)   Community HERO Treatment Survey: Characterizing Treatment Journey for Older People with HIV - (10/22/26)   Safety Analysis of BIC/LEN Single-Tablet Regimen in People With HIV Who Have Comorbidities of Dyslipidemia, Hypertension, and Diabetes Mellitus From Phase 3 of ARTISTRY-1 - (10/22/26)   Metabolic and Safety Outcomes With BIC/LEN Single-Tablet Regimen in People With HIV and Comorbidities in ARTISTRY-2 - (10/22/26)   Efficacy and Safety Outcomes With BIC/LEN Single-Tablet Regimen in People With HIV and Renal Impairment in Phase 3 of ARTISTRY-1 - (10/22/26)   Week 48 Efficacy and Safety of Doravirine/Islatravir (100 mg/0.25 mg) vs Bictegravir/Emtricitabine/Tenofovir Alafenamide in Previously Untreated Adults Living With HIV-1 With Renal Impairment - (10/22/26)   Changes in Fasting Lipids and Insulin Resistance After Switch to Doravirine/Islatravir (100 mg/0.25 mg) Once Daily: Week 96 Results From Two Phase 3 Studies in Adults Living With HIV-1 - (10/22/26)   Trends and Disparities in Statin Use Following Updated Guidelines Among People with HIV Based on 10-year Cardiovascular Risk Levels - (10/20/26)   Gait Speed Assessment During Routine HIV Care to Identify Frailty Risk - (10/20/26)   Statin Prescribing Patterns for Patients with HIV in a Post-REPRIEVE Era: A Retrospective Analysis - (10/20/26)   CKD Screening and Interventions in Patients Living with HIV and Diabetes - (10/20/26)   Implementation of 2024 Statin Guidelines in an Urban HIV Clinic: Changes in Prescribing Practices - (10/20/26)   Factors Associated with Cognitive Performance among People with HIV Aged 60 Years and Older: A Cross-sectional Study Using Normative K-MoCA z-scores - (10/20/26)   ART   Others